Explore Supplements Subscribe
The VerdictLOW CONVICTIONVerdict Score 38Worth-It: Poor ROI (20/100)

Two independent 2024 studies tested turkesterone — both found it does absolutely nothing for muscle or fat.

Summary: Turkesterone is a plant-derived compound marketed as a natural, side-effect-free muscle builder. The problem: the two best-designed human studies from 2024 found zero effect on lean mass, metabolic rate, or muscle-building hormones at doses up to 2000mg. Add rampant label fraud (67% of prod

  1. What the data actually shows: The two best-designed human studies from 2024 both found zero change in muscle, fat, metabolic rate, or muscle-building hormones — at doses up to 2000mg (about half a teaspoon of powder).
  2. The myth that won't die: The "safe, no side effects" selling point isn't evidence that it works — it's evidence that it barely does anything in the human body at all.
  3. What to watch for: 67% of commercial turkesterone products fail accuracy testing — if you're "trialling" it and think it's working, the results are almost certainly from your training, not the supplement.

Turkesterone is a plant compound that makes insects grow by plugging into their dedicated receptor. Humans don't have that receptor. Instead, turkesterone loosely fits a secondary receptor in our body — like a key cut for a different lock. It fits just enough to be interesting in a lab dish, but not enough to actually unlock anything meaningful in a living person.

That's the general answer. Your stack is different.

Check your whole stack
SH
Dr. Seth Holbrook, DPT — Doctor of Physical Therapy • Coach to 300+ clients
I built The Verdict to cut through recycled health advice and show what the evidence actually supports.

Supplement Engine

Turkesterone

Herbal / Phytoecdysteroid · Ajuga Turkestanica Extract

SKIP

The supplement that promised gains without side effects. Turns out that's because it doesn't do much of anything.

The Plain English Version

Two independent 2024 studies tested turkesterone — both found it does absolutely nothing for muscle or fat.

Turkesterone is a plant compound that helps insects grow by plugging into their own dedicated receptor — like a key fitting its exact lock. Humans don't have that receptor. Instead, turkesterone loosely fits a secondary receptor in our body — the wrong lock for this key. It's interesting in a petri dish, but in a living person, it can't turn the mechanism. To make things worse, the compound is gone from your system in about 3 hours — not nearly long enough to trigger the kind of sustained signaling that actually builds muscle.

  1. What the data actually shows: The two best-designed human studies from 2024 both found zero change in muscle, fat, metabolic rate, or muscle-building hormones — at doses up to 2000mg (about half a teaspoon of powder).
  2. The myth that won't die: The "safe, no side effects" selling point isn't proof it works — it's proof that it barely interacts with the human body at all.
  3. What to watch for: 67% of commercial turkesterone products fail accuracy testing — if you're trialling it and think it's working, the results are almost certainly from your training, not the supplement.

Want the full evidence? Keep scrolling

What People Claim

The Marketing Narrative

Turkesterone has been aggressively marketed as a "natural steroid" — a legal, side-effect-free alternative to SARMs (selective androgen receptor modulators). The pitch is compelling: all the gains, none of the risks.

"Natural plant-based anabolic compound that increases muscle protein synthesis by 20% — no hormone suppression, no liver stress."

Proponents point to studies showing 20% increases in protein synthesis in lab models and one human trial (Isenmann 2019) reporting +2.0 kg lean mass in 10 weeks. This is then used to compare turkesterone favorably to exogenous anabolic-androgenic steroids.

"HPβCD-complexed form provides up to 100x better absorption — standard turkesterone doesn't work because it can't be absorbed."

The "HPβCD advantage" angle is particularly clever marketing: it reframes all existing null results as a bioavailability problem already solved by the premium-priced product. You didn't fail — you just used the wrong form.

The safety claims are technically accurate: turkesterone does not suppress testosterone or disrupt the hormonal axis. Consumers interpret this clean safety profile as evidence of potency. It isn't.

What the Evidence Shows

By Endpoint

Claimed Benefit Verdict Key Study
Muscle mass gain (lean mass) DEBUNKED

What would change this: A mass-spec-verified, 10-12 week RCT showing DXA-confirmed lean mass gain greater than placebo in resistance-trained subjects.

 Does not work Antonio et al. 2024, N=31, DXA: -0.6 kg turkesterone vs -0.3 kg placebo (p=0.68). 4 weeks, double-blind.
IGF-1 elevation (muscle-building hormone) DEBUNKED

What would change this: A dose-response study showing significant IGF-1 elevation at any commercially available dose.

 Does not work Harris et al. 2024, N=11, crossover: no significant IGF-1 or RMR response at 1000mg or 2000mg (about a quarter to half a teaspoon) acute oral dose.
Resting metabolic rate increase DEBUNKED

What would change this: Replicated metabolic studies showing increased RMR at any dose.

 Does not work Harris et al. 2024: no main condition or time effect (p>0.05) on metabolic rate.
Muscle mass + strength (ecdysterone, related compound) WEAK

What would change this: Replication of Isenmann's positive result under the same conditions with commercial-grade product.

 Contradicted by later evidence Isenmann 2019, N=46: +2.0 kg lean mass, ↑1RM bench — BUT different compound (ecdysterone), mass-spec verified, contradicted by Wilborn 2006 and both 2024 RCTs.
Body fat reduction WEAK

What would change this: Any DXA-measured fat loss in an RCT.

 Unproven No DXA-measured fat changes in any human RCT to date.
No HPG axis suppression (safety claim) CONFIRMED

This is the one claim that holds: testosterone and LH are genuinely unchanged across all studies.

 Genuinely safe (but this isn't anabolic potency) Confirmed across multiple trials: no testosterone, LH, or reproductive hormone changes.

What Doesn't Work

  • "Natural anabolic equivalent to SARMs" — Turkesterone does not bind the androgen receptor at all. The mechanism is via a secondary receptor and translates poorly in humans.
  • "HPβCD form solves the bioavailability problem" — HPβCD improves in vitro (lab dish) solubility. There is zero peer-reviewed human data confirming superior blood levels or muscle outcomes in vivo (in a living person).
  • Once-daily dosing — A 3-hour half-life means single daily doses leave you below any effective threshold for 21 hours. Even the proposed mechanism requires sustained receptor activation.
  • "The Isenmann study proves it works" — Isenmann used ecdysterone (distinct compound), verified doses by mass spectrometry (impossible commercially), and was contradicted by two 2024 RCTs.

How It Works

The Mechanism — And Why It Breaks Down in Humans

Turkesterone belongs to the phytoecdysteroid family — plant-derived steroid-like compounds that regulate molting in insects. Here's where the mechanism gets interesting, and where it falls apart.

Why insects build muscle and humans don't

Arthropods (insects, crustaceans) have a dedicated ecdysone receptor complex (EcR/USP heterodimer) that phytoecdysteroids lock onto with high precision. Turkesterone is the right key for that lock. Humans simply don't have this receptor. It never evolved in our lineage.

In humans, the proposed pathway is: turkesterone weakly activates Estrogen Receptor beta (ERβ), which theoretically triggers PI3K/Akt signaling, which activates mTOR and p70S6K — the same downstream machinery that responds to resistance training and drives muscle protein synthesis.

In rodent cells and lab models, this pathway activation is real: up to 20% increases in protein synthesis in mouse muscle cells. The problem is what happens at every step of translation to humans:

Three translation failures

1. Weak receptor fit. Human ERβ affinity for ecdysteroids is far lower than for endogenous estrogens. The lock barely turns.

2. Half-life of ~3 hours. Turkesterone is gone from circulation in roughly 3 hours — far too brief for sustained mTOR upregulation across a recovery cycle.

3. Direct mechanism test failed. Harris et al. (2024) measured serum IGF-1 (the downstream anabolic signal) after 1000mg and 2000mg acute oral doses. Both doses produced zero significant IGF-1 elevation. The proposed anabolic mechanism does not activate in humans at oral supplemental doses.

The compound is pharmacologically interesting on paper. The human clinical translation simply doesn't exist.

The Debate

Where the Studies Disagree

Human vs Rodent Evidence

In vitro / Rodent Models

20% increase in protein synthesis in murine myotubes. Dramatic mTOR activation in cell culture. The biochemistry works beautifully.

VS

Harris 2024 — Human RCT

Zero IGF-1 response at 1000–2000mg acute oral dose in humans. The downstream mechanism that should show anabolic signaling: absent.

Why they disagree: Species barrier. Humans lack the dedicated ecdysone receptor. ERβ cross-reactivity is weak. Oral pharmacokinetics insufficient for sustained signaling.

The Isenmann vs Antonio Contradiction

Isenmann 2019 — N=46

+2.0 kg lean mass over 10 weeks with ecdysterone (12–48mg actual, independently verified by mass spectrometry). Bench press 1RM increased.

VS

Antonio 2024 — N=31

-0.6 kg lean mass over 4 weeks with 500mg labeled turkesterone (commercial product, actual yield unknown). No significant body composition change.

Why they disagree: Three compounding confounds — different compounds (ecdysterone vs turkesterone), different duration (10 vs 4 weeks), and critically: Isenmann verified actual dose by mass spec while Antonio used an off-the-shelf product where label fraud is endemic. Current evidence direction: null hypothesis. Three null RCTs (Wilborn 2006, Antonio 2024, Harris 2024) vs one positive outlier with significant confounds.

Real World vs Lab

Why Consumer Outcomes Will Be Worse Than Even the Null RCTs

Label Fraud

Lab: Researchers verify actual compound dose via LC-MS/MS mass spectrometry before the trial begins.
Reality: 67% of commercial ecdysteroid supplements fail label accuracy testing. Some products contain less than 6% of their stated dose. You may be buying a very expensive empty capsule.
MORE CONSERVATIVE

Half-Life Problem

Lab: Researchers can administer doses every 6 hours to maintain plasma concentrations, maximizing the window for any receptor activation.
Reality: Consumers take once-daily or twice-daily doses. With a ~3-hour half-life (how long it stays active in your body), this leaves 15+ hours per day sub-therapeutic — even if the product is accurately labeled.
MORE CONSERVATIVE

Training Protocol

Lab: Isenmann's positive result used a tightly controlled 10-week progressive resistance training program with verified adherence.
Reality: Antonio's null result used participants "maintaining their exercise habits" — a much closer match to how real consumers actually train. Consumer outcomes track the null result.
MORE CONSERVATIVE

Exactly How to Use It

Dosing — The Honest Answer

There is no evidence-based dose for turkesterone. The following table represents what the research found — and what it didn't.

Population Dose Tested Outcome Notes
General adult 500 mg/day (labeled) Null — no lean mass, fat, or body weight change Antonio 2024, 4 weeks, commercial product
Athletes 1000–2000 mg (about a quarter to half a teaspoon) acute Null — no IGF-1 or metabolic rate response Harris 2024, verified dose
Reference: ecdysterone (positive outlier) 12–48 mg actual ecdysterone (not turkesterone) Positive — +2.0 kg lean mass, 10 weeks Isenmann 2019 — mass-spec verified, different compound, not reproducible commercially

Practical note: If choosing to trial turkesterone despite null evidence, any meaningful attempt would require: mass-spectrometry-verified actual ecdysteroid content (most products fail this), split dosing every 6 hours (to counteract the ~3-hour half-life), and a minimum 10-week duration with structured progressive overload. None of these conditions are achievable with standard off-the-shelf commercial products.

Forms Comparison

Standard Extract

Bioavailability: Poor (<1–2% est.)

67% of products fail label accuracy. No validated population.

£25–40/month

HPβCD-Complexed

Claims 100x solubility (in vitro only)

Zero human PK or performance RCTs confirming the advantage. Unvalidated.

£50–80/month

Safety & Interactions

The Safety Profile — Genuinely Clean, But For the Wrong Reason

Turkesterone's safety profile is legitimately clean. No testosterone suppression, no liver stress, no kidney damage in any human trial. The absence of harm is real — it's just not evidence of benefit.

Anti-Estrogen Therapies (tamoxifen, aromatase inhibitors)

Turkesterone's weak ERβ receptor activity may partially work against these medications' therapeutic goals. Theoretical risk — not confirmed in human trials. Avoid concurrent use and discuss with prescriber. Severity: Moderate.

Hormone Replacement Therapy (HRT)

Weak ERβ activity adds to an already elevated estrogen environment. Risk is mild and theoretical. Discuss with prescriber if on high-dose HRT. Severity: Mild.

WADA 2025 Monitoring Program

Ecdysterone (close chemical analog of turkesterone) is listed under Anabolic Agents on the 2025 WADA Monitoring Program — in and out of competition. Not currently banned: athletes will NOT fail tests in 2025. However, future prohibition is plausible. Risk-averse competitive athletes should avoid both ecdysterone and turkesterone.

Side Effects

Side EffectIncidenceNotes
Gastrointestinal discomfort Not reported Harris 2024 tested up to 2000mg with strict GI questionnaires — no symptoms reported.
Liver stress (hepatotoxicity) Not observed Liver enzymes unchanged at 800mg labeled dose over 10 weeks in all trials.
Kidney stress Not observed Creatinine clearance unaffected; rapid renal clearance (4–5 L/h). Not a concern at supplemental doses.

Upper limit: Not established by EFSA or NIH — insufficient long-term human data. Murine LD50 >9g/kg body weight renders toxic dosing essentially impossible. Acutely safe up to 2000mg bolus confirmed in humans (Harris 2024).

The Nuance

What the Simple Answer Misses

The null verdict is clear, but three nuances are worth understanding:

The mechanism isn't wrong — it just doesn't survive the human body

Turkesterone's biochemistry is sound. ERβ activation does drive the PI3K/Akt/mTOR pathway. The problem isn't the theory — it's that human ERβ affinity for ecdysteroids is too weak, the compound clears too fast, and our biology never evolved to respond to these plant signals the way insects do. The hypothesis was reasonable. The evidence resolved it.

Who might benefit in the future (not now)

The only population with any theoretical rationale: resistance-trained athletes using mass-spectrometry-verified HPβCD-complexed forms, dosed 3–4 times daily, over a minimum 10–12 week structured progressive overload program. That product does not currently exist in commercial form. The HPβCD bioavailability claim has zero human pharmacokinetic validation.

Cost-Effectiveness

FormMonthly CostEvidence BaseBetter Alternative
Standard Ajuga Extract £25–40 Null in 2024 RCTs Creatine monohydrate £8–15/month — 30 years of STRONG evidence for muscle and strength
HPβCD-Complexed £50–80 Unvalidated in humans

Value verdict: Skip. A creatine monohydrate subscription (£8–15/month) has several decades of STRONG evidence supporting exactly what turkesterone cannot demonstrate in a single well-designed trial.

Conviction

LOW

Three null RCTs, endemic label fraud, no validated commercial form, and direct mechanism failure in the best-powered human test available.

What would change this verdict?
A single RCT meeting ALL of the following criteria:
  1. Active compound dose verified by LC-MS/MS mass spectrometry before the trial begins.
  2. Minimum 500mg/day of true turkesterone (not labeled — actual yield confirmed).
  3. Direct head-to-head comparison of HPβCD-complexed vs standard extract with human pharmacokinetic data.
  4. Minimum 10–12 week duration (not 4 weeks).
  5. Resistance-trained subjects on a supervised progressive overload program.
  6. DXA-verified lean mass as the primary endpoint.
  7. Muscle biopsies measuring fractional synthetic rate (FSR) and mTOR phosphorylation — direct evidence of the proposed mechanism.

Until this study exists, conviction stays LOW. The null hypothesis is the correct prior.

Sources

Key References

Verdict Score

How strong is the evidence for the claims in this review? Higher = more confidence the claims are supported. This does not measure how large the effect is or how important it is compared with other levers.

38 Weak support
80–100Strong evidence
60–79Mixed but supportive
40–59Uncertain
0–39Weak support ◀

Action ROI

Is this worth your time, money, effort, risk, and trust for this goal? Different from Verdict Score (evidence strength) and Leverage Map (relative importance) — Action ROI is the worth-it call once friction is priced in.

Action ROI score
20/100 Poor ROI Trust grade D
No. The two best-designed human trials found nothing, the marketing has badly outrun the science, and most products do not even contain what the label claims. Buy creatine instead.
Time
Low
Money
Medium
Effort
Low
Risk
Low
Why this score
Why it didn’t score higher
Best for
Lower ROI if
Minimum effective dose
None established. Commercial doses of 500 to 2000 mg were null in two 2024 RCTs, and no dose, form, or protocol has human efficacy data for muscle or body composition.
Track this

Get the complete dosing protocol

Evidence-scored dosing, timing, forms, and who should skip it. One page, no fluff.

Get the protocol

Related free research

Supplements
Plant Sterols & Stanols — The Verdict
 Supplements
Exogenous Ketones — The Verdict
 Supplements
Serrapeptase — Does the Silkworm Enzyme Actually Work?

There are 424 more inside

Conviction-scored verdicts on supplements, nutrition, training, physio, and recovery.

Explore all Get weekly verdicts